Conversely, agonizing the orexin receptors could be a treatment option for addressing the orexin deficiency in narcolepsy (Barker et al., 2020) and several small molecule oral OX2R agonists are currently in the pipeline (Bassetti et al., 2019; Zeitzer, 2021). Here, HCRTR2 is linked to narcolepsy.